title: Acyclovir monotherapy versus acyclovir plus beta-interferon in focal viral encephalitis in children.
abstract: Severe focal viral encephalitis is most commonly caused by herpes simplex virus (HSV), but other viruses may act as etiologic agents as well. Acyclovir (ACV) is the standard therapy for HSV encephalitis, but the mortality of 28% and defect healing rate of about 35% are still unsatisfactory. Furthermore, ACV has virtually no effect on other pathogens of viral encephalitis, except for varicella-zoster virus (VZV). It is well known that beta-interferon (beta-IFN) has a broad antiviral spectrum, and it has been demonstrated in vitro that beta-IFN in combination with acyclovir has synergistic inhibitory effects on HSV. To investigate if the combination of ACV with and without beta-IFN might also be of significance for the treatment of severe viral encephalitis, we performed a retrospective study. A case record form was sent to all 278 West German children's hospitals. The response rate was 78%. A total of 301 patients were reported, of whom 214 received specific antiviral therapy with either ACV alone (n = 179) or ACV plus beta-IFN (n = 35). No overall differences between ACV monotherapy and the combination therapy were observed. However, in a subgroup of 41 patients (ACV n = 30, ACV plus beta-IFN n = 11) who had low-density areas of the temporal lobes on cranial computed tomography scans, compatible with severe focal encephalitis, sequelae due to defect formation and mortality were significantly (p = 0.014) reduced in patients who had received combination therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Universitäts-Kinderklinik, Ludwig-Maximilians-Universität, München, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Wintergerst
authors.forename: B H
authors.initials: BH
authors.lastname: Belohradsky
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004357:Drug Synergism; D004660:Encephalitis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005490:Focal Infection / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D005858:Germany / Q000453:epidemiology; D006561:Herpes Simplex / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D006776:Hospitals, Pediatric; D006801:Humans; D007223:Infant; D016899:Interferon-beta / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D016899:Interferon-beta; D000212:Acyclovir